Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12,...
Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the...
The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer...
New initiative expands existing collaboration with Novartis focused on chronic myeloid leukemia and other rare cancers, to support patient access to care for breast cancer, the leading cause of death in women globally
The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity
Pat joins Paul Farmer, President Joe Biden, and other world leaders in "Driving innovation to advance cancer control equitably"
The Max Foundation and Novartis renew their commitment to CML patients
Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD join the board this March
We are delighted to announce that Bryan Murphy-Eustis, MBA, MPH, is joining The Max Foundation’s Executive Team as Vice President of Programs. Bryan joins the team with more than 18...
The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a...
“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.
The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer's innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.
Sign up to hear about our latest stories, news, and upcoming events.